Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
May 30, 2018 - The FDA announced the approval of Pfizer’s Xeljanz (tofacitinib), for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Return to publications